Gilder Gagnon Howe & Co’s Krystal Biotech KRYS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15M	Buy	40,296 +168	+0.4%	+$50.2K	0.15%	110
2026 Q1	$10.4M	Buy	+40,128	New	+$10.7M	0.12%	111
2024 Q1	–	Sell	-7,527	Closed	-$934K	–	268
2023 Q4	$934K	Sell	7,527 -1	-0%	-$111	0.01%	206
2023 Q3	$873K	Buy	7,528 +25	+0.3%	+$3.05K	0.01%	213
2023 Q2	$881K	Buy	7,503 +1,876	+33%	+$192K	0.01%	231
2023 Q1	$450K	Buy	+5,627	New	+$442K	0.01%	224
2021 Q2	–	Sell	-6,769	Closed	-$521K	–	429
2021 Q1	$521K	Sell	6,769 -14	-0.2%	-$1.02K	﹤0.01%	316
2020 Q4	$407K	Sell	6,783 -363	-5%	-$18.1K	﹤0.01%	288
2020 Q3	$308K	Sell	7,146 -275	-4%	-$11.9K	﹤0.01%	292
2020 Q2	$307K	Buy	7,421 +7,384	+19,957%	+$355K	﹤0.01%	264
2020 Q1	$2K	Buy	37 +15	+68%	+$785	﹤0.01%	275
2019 Q4	$1K	Hold	22	–	–	﹤0.01%	286
2019 Q3	$1K	Buy	+22	New	+$983	﹤0.01%	283

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Gilder Gagnon Howe & Co's KRYS Position: Q2 2026 in Review

Gilder Gagnon Howe & Co increased its Krystal Biotech (KRYS) stake by 0.42% in Q2 2026, buying an estimated $50.2K and bringing the position to 40,296 shares worth $15M. The position accounts for 0.15% of the portfolio, ranked #110.

Gilder Gagnon Howe & Co first reported a position in KRYS in Q3 2019 and has held it in 13 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Gilder Gagnon Howe & Co held 40,296 shares of Krystal Biotech worth $15M as of Q2 2026.
Gilder Gagnon Howe & Co bought 168 Krystal Biotech shares in Q2 2026, an estimated $50.2K.
Krystal Biotech made up 0.15% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #110 holding.
Gilder Gagnon Howe & Co first reported a position in Krystal Biotech in Q3 2019 and has held it in 13 quarters since.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.